Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REGN6569 + cemiplimab
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
REGN6569 + cemiplimab is a combination of two monoclonal antibodies under clinical investigation for the treatment of advanced solid tumor malignancies. REGN6569 is a fully human IgG1 monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR), an immune modulator expressed on regulatory T cells and activated natural killer cells, functioning primarily as an agonist. Cemiplimab is a monoclonal antibody that binds to programmed cell death-1 (PD-1) and acts as a checkpoint inhibitor. The combination is being studied to enhance anti-tumor immune responses by simultaneously promoting effector immune activity (via GITR agonism) and relieving inhibitory immune regulation (via PD-1 blockade). Both agents are administered intravenously, and the combination has advanced to phase 1/2 clinical trials, including studies in checkpoint inhibitor-naïve and resistant populations across various solid tumors, with expansion cohorts underway in head and neck cancer. Both drugs are developed by Regeneron[1][3][4][6][5].
- Brand names
- Libtayo (for cemiplimab)
- Other names
- REGN6569 + cemiplimab
02
Targets
TNFRSF18 (GITR)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on REGN6569 + cemiplimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGN6569 + cemiplimab.